Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults
Objective To explore the therapeutic efficacy of low-dose rituximab（RTX）for a relapse of steroid-dependent minimal-change nephrotic syndrome（SDMCNS）in adults.Methods From November 2018 to December 2019,8 male SDMCNS patients were retrospectively analyzed.They received low-dose RTX treatment and were...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2021-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57902752&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729442593636352 |
|---|---|
| author | Li Xiao-wei Guo Kai-qi Xu Li Huang Lan-lan Li Hui-min |
| author_facet | Li Xiao-wei Guo Kai-qi Xu Li Huang Lan-lan Li Hui-min |
| author_sort | Li Xiao-wei |
| collection | DOAJ |
| description | Objective To explore the therapeutic efficacy of low-dose rituximab（RTX）for a relapse of steroid-dependent minimal-change nephrotic syndrome（SDMCNS）in adults.Methods From November 2018 to December 2019,8 male SDMCNS patients were retrospectively analyzed.They received low-dose RTX treatment and were followed up for over 18 months.Results The median age was 28.5（18-53）years and the median follow-up period 24.5（18-28）months.And 5 and 3 cases received 2 and 3 intermittent doses of RTX 0.375 g/m<sup>2</sup> respectively.None of them had a relapse within 1 year.RTX 0.375 g/m<sup>2</sup> was repeated for 4 cases when CD19<sup>+</sup> B-cell count dropped to 6.No relapse occurred at the end of follow-up period.A comparison of clinical data at 1 year before and after RTX dosing, hormone dose declined.At the end of follow-up period, the maintenance dose was 7.5（0-20）mg/d.Two discontinued horome and frequency of relapse/hospitalization and incidence of complications decreased markedly.Except for skin rash and pruritus in one case, the remainders had no obvious adverse effects.Conclusion For SDMCNS in adults, using low-dose RTX may be repeated based upon monitoring CD19<sup>+</sup> B-cell count.Such a regimen may lower the frequency of relapse and reduce economic expenditures with fewer side effects. |
| format | Article |
| id | doaj-art-0fbdd5aa3f9d446faca85b6f68936e95 |
| institution | DOAJ |
| issn | 1671-2390 |
| language | zho |
| publishDate | 2021-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj-art-0fbdd5aa3f9d446faca85b6f68936e952025-08-20T03:09:13ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902021-01-0172773257902752Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adultsLi Xiao-weiGuo Kai-qiXu LiHuang Lan-lanLi Hui-minObjective To explore the therapeutic efficacy of low-dose rituximab（RTX）for a relapse of steroid-dependent minimal-change nephrotic syndrome（SDMCNS）in adults.Methods From November 2018 to December 2019,8 male SDMCNS patients were retrospectively analyzed.They received low-dose RTX treatment and were followed up for over 18 months.Results The median age was 28.5（18-53）years and the median follow-up period 24.5（18-28）months.And 5 and 3 cases received 2 and 3 intermittent doses of RTX 0.375 g/m<sup>2</sup> respectively.None of them had a relapse within 1 year.RTX 0.375 g/m<sup>2</sup> was repeated for 4 cases when CD19<sup>+</sup> B-cell count dropped to 6.No relapse occurred at the end of follow-up period.A comparison of clinical data at 1 year before and after RTX dosing, hormone dose declined.At the end of follow-up period, the maintenance dose was 7.5（0-20）mg/d.Two discontinued horome and frequency of relapse/hospitalization and incidence of complications decreased markedly.Except for skin rash and pruritus in one case, the remainders had no obvious adverse effects.Conclusion For SDMCNS in adults, using low-dose RTX may be repeated based upon monitoring CD19<sup>+</sup> B-cell count.Such a regimen may lower the frequency of relapse and reduce economic expenditures with fewer side effects.http://www.lcszb.com/thesisDetails?columnId=57902752&Fpath=home&index=0AdultsSteroid-dependent nephrotic syndromeMinimal-changeLow-dose rituximab |
| spellingShingle | Li Xiao-wei Guo Kai-qi Xu Li Huang Lan-lan Li Hui-min Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults Linchuang shenzangbing zazhi Adults Steroid-dependent nephrotic syndrome Minimal-change Low-dose rituximab |
| title | Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults |
| title_full | Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults |
| title_fullStr | Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults |
| title_full_unstemmed | Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults |
| title_short | Therapeutic efficacy of low-dose rituximab for steroid-dependent minimal-change nephrotic syndrome in adults |
| title_sort | therapeutic efficacy of low dose rituximab for steroid dependent minimal change nephrotic syndrome in adults |
| topic | Adults Steroid-dependent nephrotic syndrome Minimal-change Low-dose rituximab |
| url | http://www.lcszb.com/thesisDetails?columnId=57902752&Fpath=home&index=0 |
| work_keys_str_mv | AT lixiaowei therapeuticefficacyoflowdoserituximabforsteroiddependentminimalchangenephroticsyndromeinadults AT guokaiqi therapeuticefficacyoflowdoserituximabforsteroiddependentminimalchangenephroticsyndromeinadults AT xuli therapeuticefficacyoflowdoserituximabforsteroiddependentminimalchangenephroticsyndromeinadults AT huanglanlan therapeuticefficacyoflowdoserituximabforsteroiddependentminimalchangenephroticsyndromeinadults AT lihuimin therapeuticefficacyoflowdoserituximabforsteroiddependentminimalchangenephroticsyndromeinadults |